Prostate Cancer Vaccine

This page contains recent news articles, when available, and an overview of Prostate Cancer Vaccine but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.


Background information on Prostate Cancer Vaccine

[an error occurred while processing this directive]

News: Prostate Cancer Vaccine



Prostate Cancer Vaccine may Improve Survival  -  Feb 18, 2008
Online - International News Network,ISLAMABAD: A prostate cancer vaccine extends the lives of patients, even after all other treatments have failed. In what doctors are calling a potentially

Prostate cancer vaccine shows promise in trial  -  Feb 15, 2008
San Francisco Chronicle,South San Francisco shot up nearly 20 percent Friday after the company released a favorable analysis of its experimental prostate cancer vaccine GVAX.

Cell Genesys Stock Advances As Study Shows GVAX Prostate Cancer ...  -  Feb 15, 2008
CanadianBusiness.com,NEW YORK (AP) - Cell Genesys Inc. shares jumped Friday after the biotechnology company reported clinical test results showing that prostate cancer patients

Prostate cancer vaccine '5 years away'  -  Feb 5, 2008
Sydney Morning Herald,A world-first therapeutic vaccine for prostate cancer could be available in five years' time, an Australian researcher says. One in nine Australian men are

Dendreon Soars On Survival Data  -  Feb 14, 2008
Forbes,Dendreon's roller-coaster ride over the prostate cancer vaccine candidate Provenge continued Thursday, with the biotechnology company releasing a study

Experimental Vaccine Halts Prostate Cancer in Mice  -  Feb 1, 2008
Washington Post,1 (HealthDay News) -- An experimental prostate cancer vaccine has stopped the progress of the disease in 90 percent of the mice who got it,

Feuerstein's Biotech-Stock Mailbag  -  Feb 16, 2008
TheStreet.comSeveral readers asked about Dendreon's announcement Thursday of a new data analysis that correlates the potency of the prostate cancer vaccine Provenge to

Researchers Develop Prostate Cancer Vaccine, More Accurate ...  -  Feb 4, 2008
AHN...at the Norris Comprehensive Cancer Center, led the USC researchers in developing the prostate cancer vaccine, which still needs testing on humans.

Vaccine prevents prostate cancer in mice  -  Feb 1, 2008
United Press International1 (UPI) -- Researchers at the University of Southern California have developed a prostate cancer vaccine for mice that prevented cancer in 90 of lab animals

The Fight Against Prostate Cancer Progresses  -  Feb 4, 2008
Ivanhoe,...(Ivanhoe Newswire) -- Good news for men: a new prostate cancer vaccine proven powerful in mice may also prevent the disease in humans.

Prostate Cancer: Watchful Wait or Vaccinate?  -  Jan 31, 2008
Newswise (press release)Newswise — Researchers at the University of Southern California have developed a prostate cancer vaccine that prevented the development of cancer in 90

Oral flu vaccine may hold promise  -  Feb 5, 2008
Chicago Tribune,Researchers at the University of Southern California have developed a prostate cancer vaccine that prevented cancer in 90 percent of young mice genetically

QualityStocks.net "Top Movers and Shakers" for 2/14/2008  -  Feb 14, 2008
TransWorldNews (press release),While Dendreon Corporation still awaits the US approval of Dendreon drug candidate and prostate cancer vaccine Provenge, the company was able to release a

Ten Stocks Under $10: Looking Out A Year  -  Feb 18, 2008
24/7 Wall St.,DNDN's prostate cancer vaccine candidate Provenge showed encouraging results in clinical trials. The company also got patent approval for the drug in Europe

Premarket Movers: Baidu.com Gains  -  Feb 14, 2008
Forbes,...of volatile biotech Dendreon Corp. jumped after the company posted survival data for its experimental Provenge treatment for prostate cancer vaccine.

2007 FDA drug approvals: a year of flux  -  Feb 1, 2008
Nature.com (subscription),Perhaps the most prominent was Provenge (Sipuleucel-T; Dendreon), a pioneering prostate cancer vaccine. In May 2007, the FDA asked for more data about the

Call Trading Spikes on Dendreon  -  Jan 28, 2008
Schaeffers Research,On January 15, European authorities granted Dendreon's prostate cancer vaccine candidate Provenge a broad patent, which covers Provenge's composition along

Genitope's vaccine trial misses goal, stock drops  -  Dec 20, 2007
Guardian Unlimited,Dendreon Corp, another cancer vaccine maker, has not yet won regulatory approval for its prostate cancer vaccine Provenge. Genitope stock closed down $1.65

FDA’s Refusal to Approve New Cancer Vaccine - The Plot Thickens ...  -  Nov 29, 2007
Lawyers and Settlements...patients over the decision not to approve Provenge, a new life-extending prostate cancer vaccine, announced that a judge had dismissed the lawsuit.

MyVax Trial Failure Leaves Firm Hopeful, Others Not So  -  Dec 21, 2007
BioWorld Online,Dendreon Corp. nearly pulled it off this summer, gaining a thumbs up from an FDA advisory committee for prostate cancer vaccine Provenge (sipuleucel T)

Lawmakers Call for Investigation Into FDA's Provenge Decision  -  Dec 17, 2007
FDA news (subscription),Congress are calling on the House Energy and Commerce Committee to investigate why the FDA did not approve Dendreon’s prostate cancer vaccine Provenge.

Probe sought into FDA drug rejection By Gregory Lopes  -  Dec 14, 2007
Washington Times,By Gregory Lopes Lawmakers are seeking a congressional investigation into the Food and Drug Administration's rejection of a prostate cancer vaccine.

QualityStocks.net "Top Movers and Shakers" for 12/13/2007  -  Dec 13, 2007
TransWorldNews (press release),Administration would accept an analysis of data from a current clinical trial to supplement the marketing application for its prostate cancer vaccine.

Judge Dismisses Parts of Provenge Lawsuit Against FDA  -  Nov 30, 2007
FDA news (subscription),...parts of a lawsuit filed by a nonprofit group to get the FDA to reverse a decision that delayed approval of Dendreon’s prostate cancer vaccine Provenge.

Dendreon, Other "Cancer Pharms" Get Investor Ratings  -  Oct 1, 2007
CNBC,For now, he sees DNDN shares trading in a fair value range but adds, "Although we believe that Provenge (Dendreon's prostate cancer vaccine) is an active

News source: Business Wire  -  Oct 15, 2007
Genetic Engineering News (press release),Now, Aureon's powerful technology platform will be used, in a complementary way to assist research that may have implications for prostate cancer vaccine

Sector Glance: Biotechs Mixed  -  Oct 11, 2007
Houston Chronicle,Dendreon Corp. also received a "Market Perform" rating, citing regulatory issues with the prostate cancer vaccine candidate Provenge.

Wachovia Starts Dendreon (DNDN) at Market Perform  -  Oct 10, 2007
StreetInsider.com (subscription),The firm said, "Prior to and following an Approvable Letter from the FDA for Provenge, Dendreon's prostate cancer vaccine has gained significant market

Breast cancer vaccine looks safe, study shows  -  Aug 17, 2007
ReutersDendreon Corporation, maker of the Provenge prostate cancer vaccine, calls the new vaccine Neuvenge. It targets a type of breast cancer called

Dendreon's Breast Cancer Vaccine Safe, But Will It Deliver  -  Aug 20, 2007
News Locale,The new vaccine developed by Denderon is an extension of the Provenge prostate cancer vaccine. The new vaccine was tested in a Phase I trial involving 19

Breast Cancer Vaccine Appears Safe For Use  -  Aug 24, 2007
Vaccine Rx (press release),The Dendreon Corporation's Neuvenge is made using immune cells from the cancer patient; the company also produces the Provenge prostate cancer vaccine.

Prostate cancer: One man's journey  -  Aug 21, 2007
NorthJersey.com,In March, an advisory panel from the Food and Drug Administration approved a new prostate cancer vaccine, called Provenge. The drug, manufactured by

Federal Panel Announces Safety Of Provenge  -  Aug 27, 2007
Vaccine Rx (press release),A panel of the Food and Drug Administration (FDA) recently voted the Provenge prostate cancer vaccine to be safe for use. The panel further believes that

A new vaccine designed to treat breast cancer appears to be safe ...  -  Aug 25, 2007
TopCancerNews.com,The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast

Ahead of the Bell: Dendreon Rises  -  Aug 20, 2007
Forbes,...reaching an all-time high of $25.25 after a Food and Drug Administration panel recommended approval of the company's prostate cancer vaccine Provenge.

Japan nuclear plant won’t produce  -  Aug 19, 2007
Chicago Daily Herald,O), maker of the Provenge prostate cancer vaccine, calls the new vaccine Neuvenge. It targets a type of breast cancer called her2/neu-positive breast cancer

Advancing on better treatment  -  Aug 7, 2007
Miami Herald,In March, an advisory panel from the Food and Drug Administration approved a new prostate cancer vaccine, called Provenge. The drug, manufactured by

Biotech gangsters?  -  07 Jul 2007
HeraldNet,This story has a local angle: This all revolves around Dendreon's Provenge, the prostate cancer vaccine that has become the center of controversy since the

Dendreon Rises On Cancer Report  -  Jul 3, 2007
Forbes,However, according to the article, a review of five prostate cancer vaccine trials suggested that many of these same drugs could help patients live longer

Therapeutic Cancer Vaccine Trials  -  Jul 5, 2007
MedIndia,In a review of five prostate cancer vaccine trials, NCI researchers offer evidence that patients who receive vaccines may respond better to subsequent

Dendreon Gets Divorced From Any Sane Reality  -  Jul 5, 2007
TheStreet.com...more evidence that Dendreon (DNDN - Cramer's Take - Stockpickr) is in no way a fundamental stock story tied to its Provenge prostate cancer vaccine.

Pharma Blog Watch  -  Jul 3, 2007
FDA news (subscription),In his blog, Mike Huckman discusses the recent success of Dendreon with its prostate cancer vaccine, Provenge. Although the company’s product has received

WZZM adds Sunday am health show  -  Jul 2, 2007
The Grand Rapids Press,..."The show also is about medical breakthroughs happening right here in West Michigan, such as the prostate cancer vaccine that's being developed and tested

Provenge maker faces securities suit  -  Jun 13, 2007
United Press InternationalNEW YORK, June 13 (UPI) -- US biotech firm Dendreon -- developer of prostate cancer vaccine Provenge -- is facing a class-action lawsuit over alleged

Coming of Age  -  Jun 7, 2007
Drug Discovery & Development,Seattle, Provenge (sipuleucel-T), a highly anticipated and potential blockbuster prostate cancer vaccine, pending additional efficacy data.

MMI success helps shares  -  Jun 8, 2007
Cambridge Evening News,MMI's shares rose 9p on the news, which follows last month's announcement regarding success with a prostate cancer vaccine.

Activists Urge FDA, Congress To Approve Experimental Prostate ...  -  05 Jun 2007
Kaiser network.org,...on Tuesday attended a rally in Washington, DC, to urge FDA to approve an experimental prostate cancer vaccine, the Philadelphia Inquirer reports.

FDA Requests More Data for Prostate Cancer Vaccine  -  May 23, 2007
Medscape (subscription)May 23, 2007 (Anaheim) — The US Food and Drug Administration (FDA)’s request for more data before approving a prostate cancer vaccine was a blow to many

Vakzine Projekt Management Reports Positive Clinical Trial Results ...  -  Jun 1, 2007
PharmaLive.com (press release),HANOVER, Germany--(BUSINESS WIRE)--Jun 1, 2007 - A therapeutic vaccine developed by the German company VPM to battle prostate cancer promises new hope for

Vakzine Projekt Management Reports Positive Clinical Trial Results ...  -  Jun 1, 2007
Genetic Engineering News (press release),A therapeutic vaccine developed by the German company VPM to battle prostate cancer promises new hope for cancer patients. The results of a successfully

Vakzine Projekt Management Reports Positive Clinical Trial Results ...  -  Jun 1, 2007
Business Wire (press release),HANOVER, Germany--(BUSINESS WIRE)--A therapeutic vaccine developed by the German company VPM to battle prostate cancer promises new hope for cancer patients

Interim data strong for Inovio Bio prostate cancer vaccine  -  May 22, 2007
San Diego Daily Transcript (subscription),...(AMEX: INO) announced Tuesday that interim data from a clinical study of an experimental DNA-based prostate cancer vaccine demonstrated that the company’s

Inovio’s Delivery Technology Boosts Cancer Vaccine Potency  -  May 24, 2007
Seeking Alpha,Sara Calabro submits: Data released Tuesday from a study of an experimental prostate cancer vaccine showed that Inovio Biomedical’s (INO) delivery system

Inovio Biomedical's DNA Delivery Technology Significantly Enhances ...  -  May 23, 2007
PipelineReview.com (press release),DNA-based prostate cancer vaccine demonstrated that Inovio's DNA delivery technology significantly enhanced the potency of the gene-based vaccine.

Dendreon Cuts 40 Jobs Over Likely Delay in Cancer Vaccine Launch  -  May 21, 2007
Therapeutics Daily (subscription) (press release),...connected with the marketing of Provenge, its experimental prostate cancer vaccine for which US regulators demanded more data before granting approval.

Group slams FDA for Provenge delay  -  May 23, 2007
United Press InternationalNEW YORK, May 23 (UPI) -- A patient advocacy group Wednesday vowed to fight a decision by US regulators to delay approval of prostate cancer vaccine

Dendreon Denial: This Surge Is Silly  -  May 31, 2007
TheStreet.comThe Food and Drug Administration will require more clinical data on Provenge before the prostate cancer vaccine is considered. That data will come from the

Inovio's electroporation tech delivers the goods in trial  -  May 24, 2007
BiopharmaReporter.com,...data from a Phase I/II clinical study showing that its MedPulser system significantly enhanced the potency of an experimental prostate cancer vaccine.

Inovio Biomedical's Partners to Present New Data from Two Cancer ...  -  May 17, 2007
PharmaLive.com (press release),Dr. Christian Ottensmeier of the University of Southampton will present data relating to a prostate cancer vaccine. Dr. Richard Heller of the University of

Friday's ETF Winners & Losers  -  Jun 1, 2007
TheStreet.com...provided confirmation it will accept either a positive interim or final analysis of survival in order to approve the prostate cancer vaccine, Provenge.

Pharma Sector: Few Newsmakers Of The Week - Ista, Wyeth, Bristol ...  -  May 12, 2007
Trading Markets,The company was issued an approvable letter for its investigational prostate cancer vaccine, Provenge by the FDA. The stain of this news cratered the share

Thursday's Small-Cap Winners & Losers  -  May 31, 2007
TheStreet.com...after the Food and Drug Administration detailed what extra information it will require for approval of the biotech's prostate-cancer vaccine, Provenge.

Ahead of the Bell: Dendreon Drops  -  May 24, 2007
Forbes,JMP Securities downgraded the stock, saying the biotechnology company does not appear optimistic its prostate cancer vaccine will be approved soon.

FDA seeks more data on Dendreon's Provenge  -  May 9, 2007
United Press InternationalSEATTLE, May 9 (UPI) -- Dendreon said Wednesday the US Food and Drug Administration requested additional clinical data about its prostate cancer vaccine


Search the web for more resources on Prostate Cancer Vaccine
 
Web health.mongabay.com





Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com


Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.


COPYRIGHT 2006 MONGABAY.COM